Michael Gladstone is a partner and focuses on building new therapeutics companies, primarily in the areas of immunology and oncology.
Michael is a co-founder, acting CEO, and board member of Third Harmonic Bio, co-founder and board observer of Q32 Bio, and a board member of Day One Biopharmaceuticals (NASDAQ: DAWN) and Versanis Bio. He is also a board observer for Xilio Therapeutics, IFM Therapeutics LLC, and Obsidian Therapeutics. Michael was previously a board observer for Akero (NASDAQ: AKRO), AvroBio (NASDAQ: AVRO), Delinia (acquired by Celgene), and Replimune (NASDAQ: REPL). Michael was a member of the founding teams of several Atlas-originated companies, including Padlock Therapeutics (acquired by BMS), Surface Oncology (NASDAQ: SURF), and IFM Therapeutics Inc. (acquired by BMS; and its spinout IFM Tre acquired by Novartis).
Prior to joining Atlas in 2012, Michael worked at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. Previously, Michael worked in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center where he led research on HIV vaccines with Harvard Medical School Professor Norman Letvin.
Michael serves as an advisor to several organizations, including as a Scientific Advisory Board member of the Institute for Protein Innovation, a non-profit founded by Tim Springer to innovate new protein-based research tools and therapies to cure intractable diseases. Michael is on the Corporate Advisory Committee for National Tay-Sachs and Allied Diseases, a national organization focused on funding research, promoting awareness, and supporting families affected by Tay-Sachs and related genetic diseases.
Michael received an AB in biochemical sciences with highest honors from Harvard College, where he graduated magna cum laude and was awarded the Harvard College Scholarship and Herchel Smith Undergraduate Research Fellowship. In his spare time, he enjoys spending time with his family, reading, and playing basketball enthusiastically but with rapidly declining effectiveness.